Abeona Therapeutics shares surge 19.90% after-hours after strong Q3 earnings, Zevaskyn demand, and major insurer coverage.

Abeona Therapeutics (ABEO) surged 19.90% in after-hours trading following its Q3 2025 earnings report and updates on Zevaskyn, its gene therapy for RDEB. The company narrowed its net loss to $5.2M (vs. $30.3M in Q3 2024), attributed to optimized R&D spending and operational efficiency. Key drivers included strong patient demand, with identified eligible patients doubling to ~30, and broad coverage of Zevaskyn by major insurers (UnitedHealthcare, Cigna, Aetna, Anthem, and Blue Cross Blue Shield plans). These developments, alongside a $207.5M cash reserve supporting two years of operations, overshadowed a one-quarter delay in patient treatments due to a resolved sterility assay issue. The stock’s rally reflected optimism around Zevaskyn’s commercial potential and Abeona’s strategic progress in scaling treatment centers and securing market access.